McKesson Corporation (MCK), a major player in the pharmaceutical and biotech sectors, has been extensively covered in recent news. Noted investment advisor
Jim Cramer has endorsed the stock multiple times, referring to it as a 'Trump Stock' and advising investors to purchase it in a 'pyramid style'. McKesson suffered a dip of 15.2% in Q3 but despite this downturn,
HighTower Advisors and several others have decreased their stakes.
Mizuho assigned a Neutral rating, underlining their
oncology growth strategy as a key factor. This neutral rating comes as the stock underperforms compared to competitors. Meanwhile, institutional owners hold an impressive
89% stake in the company. Cited for its
massive returns over the past five years, its earnings quality, and its undervalued status, many see McKesson as an appealing long-term investment. The company has further bolstered its financial position by declaring quarterly dividends and increasing its
full-year EPS guidance following a Q2 earnings beat. Future prospects remain bright as both Q1 and Q2 2025 earnings show strong
revenue and
strategic growth. However, recent sale of businesses and revenue shortcoming in the U.S. pharmaceutical segment weigh on the short-term outlook.
Mckesson Corporation MCK News Analytics from Tue, 07 May 2024 07:00:00 GMT to Sat, 07 Dec 2024 10:48:38 GMT -
Rating 5
- Innovation 4
- Information 8
- Rumor 6
